Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ARRY > Summary

Array BioPharma, Inc.
(ARRY)

2.40USD   Down 0.01 (0.41%)   
At 2:30AM IST
 Array BioPharma, Inc. (NGM:ARRY) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 2.40USD
Trade Time:2:30AM IST
Change:Down 0.01 (0.41%) 
Prev Close:2.41
Open:2.43
Bid:1.50 x 100
Ask:3.33 x 100
1y Target Est:5.61
Day's Range:2.35 - 2.44
52wk Range:1.68 - 4.65
Volume:250,779
Avg Vol (3m):635,533
Market Cap:118.34M
P/E (ttm):N/A
EPS (ttm):-2.48
Div & Yield:N/A (N/A%)
Add ARRY to Portfolio   Download Data

HEADLINES

 
•ARRAY BIOPHARMA INC Financials - EDGAR Online Financials  - Fri, Feb 5
•Dow down 26; Array BioPharma up 7% - bizjournals.com  - Thu, Feb 4
•Beacon Equity Issues BioPharmaceutical Stock Alert for Array BioPharma Inc. - GlobeNewswire  - Wed, Feb 3
•Lower Q2 Loss for Array Bio - Zacks.com  - Wed, Feb 3
•Array BioPharma Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript - Seeking Alpha  - Wed, Feb 3
•Array BioPharma, Sterling Financial: Early Volume Plays - TheStreet.com  - Tue, Feb 2
•New Star Analyst Rankings for Array BioPharma Inc. - StarMine  - Tue, Feb 2
•ARRAY BIOPHARMA INC Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Tue, Feb 2
•UPDATE - Array BioPharma posts smaller-than-expected Q2 loss - Reuters  - Tue, Feb 2
•ARRAY BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib - EDGAR Online  - Tue, Feb 2
•Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2010 - Business Wire  - Tue, Feb 2
» More Headlines for ARRY...

ANALYST

 
EPS Est (next year) (Jun-10) :-2.01
EPS Est (in 2 years) (Jun-11) :-1.81
Avg Rec (current)*:2.1
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer, inflammatory, and metabolic diseases in North America, Europe, and Asia Pacific.

» Full Company Profile